Experimental t cell therapy targets sarcoma in small early trial
NCT ID NCT03462316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a personalized cell therapy for people with advanced bone or soft tissue sarcoma that had stopped responding to standard treatment. The therapy uses the patient's own immune cells, modified to better recognize and attack cancer cells carrying a specific marker called NY-ESO-1. Only 2 participants were enrolled, and the main goal was to check safety and find the right dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-Sen Univerisity
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a targeted pill stall advanced sarcomas?
- Smartwatch exercise plan aims to rebuild fitness in young cancer survivors
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells